Safety of abdominal paracentesis in hospitalised patients receiving uninterrupted therapeutic or prophylactic anticoagulants.

IF 1.8 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Internal Medicine Journal Pub Date : 2024-11-11 DOI:10.1111/imj.16572
Joseph Raco, John Bufalini, James Dreer, Vraj Shah, Lauren King, Li Wang, Matthew Evans
{"title":"Safety of abdominal paracentesis in hospitalised patients receiving uninterrupted therapeutic or prophylactic anticoagulants.","authors":"Joseph Raco, John Bufalini, James Dreer, Vraj Shah, Lauren King, Li Wang, Matthew Evans","doi":"10.1111/imj.16572","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Abdominal paracentesis is a frequently performed procedure in hospitalised patients with ascites. Concurrently, most hospitalised adult patients receive pharmacologic anticoagulation, either for therapeutic purposes or prophylactically to prevent venous thromboembolism. Despite this, minimal evidence exists to guide management of anticoagulant therapy pre- and post-paracentesis.</p><p><strong>Aims: </strong>The authors aimed to investigate the safety of abdominal paracentesis in hospitalised patients receiving therapeutic or prophylactic anticoagulation, including in patients for whom these medications were withheld periprocedurally.</p><p><strong>Methods: </strong>TriNetX, an electronic health record data set, was queried to identify patients between the ages of 18 and 80 years who received an abdominal paracentesis while hospitalised at the authors' institution between September 2017 and June 2022. Patients receiving prophylactic anticoagulation (137), therapeutic anticoagulation (74) and no anticoagulation because of coagulopathy or thrombocytopenia (15) were compared. Rates of withholding anticoagulation, performing service, pre- and post-paracentesis haemoglobin, bleeding complications, thrombotic complications and need for red blood cell transfusion were analysed.</p><p><strong>Results: </strong>Procedure-related bleeding complications occurred in two (1.4%) patients in the prophylactic group and 0 (0%) patients in the therapeutic group (P = 0.54). No thrombotic complications occurred. Rates of red blood cell transfusions post-paracentesis were similar between groups. Analysis of secondary end-points identified significant differences in rates of withholding anticoagulation and mean change in haemoglobin between performing services.</p><p><strong>Conclusion: </strong>Performance of abdominal paracentesis in patients receiving therapeutic or prophylactic anticoagulation appears to be safe regardless of whether anticoagulation was interrupted periprocedurally, with low rates of bleeding complications, thrombotic complications or need for red blood cell transfusions post-paracentesis.</p>","PeriodicalId":13625,"journal":{"name":"Internal Medicine Journal","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Internal Medicine Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/imj.16572","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Abdominal paracentesis is a frequently performed procedure in hospitalised patients with ascites. Concurrently, most hospitalised adult patients receive pharmacologic anticoagulation, either for therapeutic purposes or prophylactically to prevent venous thromboembolism. Despite this, minimal evidence exists to guide management of anticoagulant therapy pre- and post-paracentesis.

Aims: The authors aimed to investigate the safety of abdominal paracentesis in hospitalised patients receiving therapeutic or prophylactic anticoagulation, including in patients for whom these medications were withheld periprocedurally.

Methods: TriNetX, an electronic health record data set, was queried to identify patients between the ages of 18 and 80 years who received an abdominal paracentesis while hospitalised at the authors' institution between September 2017 and June 2022. Patients receiving prophylactic anticoagulation (137), therapeutic anticoagulation (74) and no anticoagulation because of coagulopathy or thrombocytopenia (15) were compared. Rates of withholding anticoagulation, performing service, pre- and post-paracentesis haemoglobin, bleeding complications, thrombotic complications and need for red blood cell transfusion were analysed.

Results: Procedure-related bleeding complications occurred in two (1.4%) patients in the prophylactic group and 0 (0%) patients in the therapeutic group (P = 0.54). No thrombotic complications occurred. Rates of red blood cell transfusions post-paracentesis were similar between groups. Analysis of secondary end-points identified significant differences in rates of withholding anticoagulation and mean change in haemoglobin between performing services.

Conclusion: Performance of abdominal paracentesis in patients receiving therapeutic or prophylactic anticoagulation appears to be safe regardless of whether anticoagulation was interrupted periprocedurally, with low rates of bleeding complications, thrombotic complications or need for red blood cell transfusions post-paracentesis.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
不间断服用治疗性或预防性抗凝剂的住院病人进行腹腔穿刺的安全性。
背景:腹腔穿刺术是住院腹水患者经常要做的手术。与此同时,大多数住院成人患者都会接受药物抗凝治疗,以达到治疗目的或预防静脉血栓栓塞。尽管如此,用于指导腹腔穿刺术前后抗凝治疗管理的证据却少之又少。目的:作者旨在调查接受治疗性或预防性抗凝治疗的住院患者进行腹腔穿刺术的安全性,包括在术前停用这些药物的患者:对电子健康记录数据集 TriNetX 进行了查询,以确定 2017 年 9 月至 2022 年 6 月期间在作者所在机构住院期间接受腹腔穿刺术的 18 至 80 岁患者。对接受预防性抗凝治疗(137 例)、治疗性抗凝治疗(74 例)和因凝血功能障碍或血小板减少而未接受抗凝治疗(15 例)的患者进行了比较。分析了暂停抗凝、提供服务、穿刺前后血红蛋白、出血并发症、血栓并发症和输红细胞需求的比率:结果:预防组有两名患者(1.4%)出现了与手术相关的出血并发症,治疗组则为零例(0%)(P=0.54)。无血栓并发症发生。两组患者在腹腔穿刺术后输注红细胞的比例相似。对次要终点的分析发现,在暂停抗凝治疗率和血红蛋白平均变化率方面,治疗组和治疗组之间存在显著差异:结论:在接受治疗性或预防性抗凝治疗的患者中实施腹腔穿刺术似乎是安全的,无论是否在术前中断抗凝治疗,出血并发症、血栓并发症或穿刺术后输注红细胞的发生率都很低。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Internal Medicine Journal
Internal Medicine Journal 医学-医学:内科
CiteScore
3.50
自引率
4.80%
发文量
600
审稿时长
3-6 weeks
期刊介绍: The Internal Medicine Journal is the official journal of the Adult Medicine Division of The Royal Australasian College of Physicians (RACP). Its purpose is to publish high-quality internationally competitive peer-reviewed original medical research, both laboratory and clinical, relating to the study and research of human disease. Papers will be considered from all areas of medical practice and science. The Journal also has a major role in continuing medical education and publishes review articles relevant to physician education.
期刊最新文献
Final results of the National Oncology Mentorship Program 2023 and its impact on burnout and professional fulfilment. Platelet factor 4 immune disease: medical emergencies that look like heparin-induced thrombocytopenia. Correction to: 'Managing cancer-related pain in the setting of proven IgE-mediated opioid anaphylaxis'. Real-world impact of pembrolizumab availability for deficient mismatch repair metastatic colorectal cancer. Environmental impact of large language models in medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1